Fig. 6: mGIPR-Ab/P1 peptide–antibody conjugate treatment and CNS GIPR KO result in gene expression profile changes in WAT. | Nature Metabolism

Fig. 6: mGIPR-Ab/P1 peptide–antibody conjugate treatment and CNS GIPR KO result in gene expression profile changes in WAT.

From: GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice

Fig. 6: mGIPR-Ab/P1 peptide–antibody conjugate treatment and CNS GIPR KO result in gene expression profile changes in WAT.

Transcriptomic analysis was conducted on WAT from male DIO Giprfl/fl, GiprSyn−/−, Glp1rfl/fl and Glp1rWnt1−/− mice treated with either vehicle or mGIPR-Ab/P1. Samples were analysed for differential gene expression using DESeq2, and Ingenuity Pathway Analysis was used to identify the most significantly affected pathways. a,c, Bubble plot representing pathways enriched for DEGs in GiprSyn−/− vehicle-treated and Giprfl/fl mGIPR-Ab/P1-treated mice (a), and Glp1rWnt1−/− vehicle-treated and Glp1rfl/fl mGIPR-Ab/P1-treated mice (c). Bubble size represents P value and colour shade represents z-score/enrichment score for each pathway. b,d, Heatmap for top five genes per enriched pathway in GiprSyn−/− vehicle-treated and Giprfl/fl mGIPR-Ab/P1-treated mice (b) and Glp1rWnt1−/− vehicle-treated and Glp1rfl/fl mGIPR-Ab/P1-treated mice (d). Top five genes were selected based on biological relevance and statistical significance. In a and c, right-tailed Fisher’s exact test; n = 5 per group. Activ. of gene express., activation of gene expression; ECM, extracellular matrix; superpath., superpathway; veh, vehicle.

Source data

Back to article page